BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21-40. [PMID: 29447987 DOI: 10.1016/j.cmi.2018.02.002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 Faguer S, Belliere J, Ribes D. Complement C5-blocking Agent in Refractory Dermatomyositis. J Rheumatol 2018;45:1710-1. [PMID: 30219762 DOI: 10.3899/jrheum.180060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fernández-Ruiz M, Aguado JM. Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. Curr Transplant Rep 2020;:1-11. [PMID: 33110739 DOI: 10.1007/s40472-020-00306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
4 Sánchez-Martínez F, Arenas-Miras M, Jové-Caballé N, Knobel-Freud H; COVID-19 Infectious Disease Team Hospital del Mar. Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results. Arch Bronconeumol 2021;57 Suppl 2:58-9. [PMID: 33714660 DOI: 10.1016/j.arbres.2021.02.003] [Reference Citation Analysis]
5 Gavriilaki E, Sakellari I, Gavriilaki M, Anagnostopoulos A. A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int J Mol Sci 2020;21:E3886. [PMID: 32485958 DOI: 10.3390/ijms21113886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist 2020;13:513-32. [PMID: 32110062 DOI: 10.2147/IDR.S233137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lasagni C, Bigi L, Conti A, Pellacani G. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J Dermatolog Treat 2018;29:5-8. [PMID: 30403898 DOI: 10.1080/09546634.2018.1543843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Costagliola G, Spada E, Consolini R. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. Pediatr Rheumatol Online J 2021;19:68. [PMID: 33947420 DOI: 10.1186/s12969-021-00559-5] [Reference Citation Analysis]
9 Fernández-ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado J, Delaloye J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection 2018;24:S2-9. [DOI: 10.1016/j.cmi.2018.01.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
10 Pham-Huy A, Sadarangani M, Huang V, Ostensen M, Castillo E, Troster SM, Vaudry W, Nguyen GC, Top KA. From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Rev Clin Immunol 2019;15:221-9. [PMID: 30570400 DOI: 10.1080/1744666X.2019.1561282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
11 Kalogeropoulos CI, Papathanasiou KA, Tsagkaraki I, Giannopoulos G, Bamias A, Boutati EI. A Case of Meningococcal and HSV-2 Meningitis in a Patient Being Treated with Ustekinumab for Pityriasis Rubra Pilaris. Eur J Case Rep Intern Med 2020;7:001615. [PMID: 32789127 DOI: 10.12890/2020_001615] [Reference Citation Analysis]
12 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
13 Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the Era of Targeted Therapies: Mapping the Road Ahead. Front Med (Lausanne) 2020;7:336. [PMID: 32974356 DOI: 10.3389/fmed.2020.00336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lafayette RA, Rovin BH, Reich HN, Tumlin JA, Floege J, Barratt J. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep 2020;5:2032-41. [PMID: 33163724 DOI: 10.1016/j.ekir.2020.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Hanitsch LG. [Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency]. Internist (Berl) 2022. [PMID: 35412057 DOI: 10.1007/s00108-022-01326-8] [Reference Citation Analysis]
18 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
19 Brown RA, Barbar-Smiley F, Yildirim-Toruner C, Ardura MI, Ardoin SP, Akoghlanian S. Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. Pediatr Rheumatol Online J 2021;19:84. [PMID: 34098976 DOI: 10.1186/s12969-021-00581-7] [Reference Citation Analysis]
20 Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018;7:212557. [PMID: 30459819 DOI: 10.7573/dic.212557] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
21 Malaquias MAS, Gadotti AC, Motta-Junior JDS, Martins APC, Azevedo MLV, Benevides APK, Cézar-Neto P, Panini do Carmo LA, Zeni RC, Raboni SM, Fonseca AS, Machado-Souza C, Moreno-Amaral AN, de Noronha L. The role of the lectin pathway of the complement system in SARS-CoV-2 lung injury. Transl Res 2021;231:55-63. [PMID: 33221483 DOI: 10.1016/j.trsl.2020.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
23 Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781-91. [PMID: 30198355 DOI: 10.1080/14787210.2018.1521270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
24 Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000Res 2019;8:F1000 Faculty Rev-1202. [PMID: 31372213 DOI: 10.12688/f1000research.17836.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Cento V, Alteri C, Mancini V, Gatti M, Lepera V, Mazza E, Moioli MC, Merli M, Colombo J, Orcese CA, Bielli A, Torri S, Gasparini LE, Vismara C, De Gasperi A, Brioschi P, Puoti M, Cairoli R, Lombardi G, Perno CF. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. Mycoses 2020;63:1299-310. [PMID: 32810888 DOI: 10.1111/myc.13170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opin Drug Saf 2019;18:1161-70. [PMID: 31594389 DOI: 10.1080/14740338.2019.1675634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
29 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Burlando M, Molle MF, Cozzani E, Parodi A. Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report. Case Rep Dermatol 2021;13:244-7. [PMID: 34054460 DOI: 10.1159/000509178] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P, McKane W, Tattersall RS. Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases. Int J STD AIDS 2020;31:808-12. [PMID: 32631210 DOI: 10.1177/0956462420915394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
32 Coll RC. Role reversal: adaptive immunity instructs inflammasome activation for anti-viral defence. EMBO J 2019;38:e103533. [PMID: 31617599 DOI: 10.15252/embj.2019103533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Fujita Y, Terashita M, Yazawa M, Yamasaki Y, Imamura T, Kibayashi J, Sawai T, Hidaka Y, Ohtani K, Inoue N, Shibagaki Y. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding. Intern Med 2020;59:93-9. [PMID: 31902910 DOI: 10.2169/internalmedicine.3315-19] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 2020;79:1532-43. [PMID: 32963049 DOI: 10.1136/annrheumdis-2020-217092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
35 Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications. J Innate Immun 2018;10:455-64. [PMID: 30149378 DOI: 10.1159/000491439] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
36 Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol 2020;146:1-7. [PMID: 32344056 DOI: 10.1016/j.jaci.2020.04.021] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 60.5] [Reference Citation Analysis]
37 Multani A, Ho DY. JC Polyomavirus Infection Potentiated by Biologics. Infect Dis Clin North Am 2020;34:359-88. [PMID: 32444013 DOI: 10.1016/j.idc.2020.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
38 Saito M, Harada S, Ogasawara R, Izumiyama K, Mori A, Morioka M, Kondo T. Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review. Int J Gen Med 2020;13:403-6. [PMID: 32765045 DOI: 10.2147/IJGM.S255298] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Passante M, Napolitano M, Dastoli S, Bennardo L, Fabbrocini G, Nisticò SP, Patruno C. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther 2021. [PMID: 34427028 DOI: 10.1111/dth.15111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73. [PMID: 30428753 DOI: 10.1080/09546634.2018.1544413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A. Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. World J Clin Cases 2021; 9(19): 4918-4938 [PMID: 34307544 DOI: 10.12998/wjcc.v9.i19.4918] [Reference Citation Analysis]
42 Bejan-Angoulvant T, Alexandre J. [Mechanism of action and adverse effects of monoclonal antibodies]. Med Sci (Paris) 2019;35:1114-20. [PMID: 31903925 DOI: 10.1051/medsci/2019208] [Reference Citation Analysis]
43 Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, Burchard G, Föll D, Garbe E, Hecht J, Müller-ladner U, Niehues T, Überla K, Vygen-bonnet S, Weinke T, Wiese-posselt M, Wojcinski M, Zepp F. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsbl 2019;62:494-515. [DOI: 10.1007/s00103-019-02905-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 20.0] [Reference Citation Analysis]
44 Kahler CM, Nawrocki KL, Anandan A, Vrielink A, Shafer WM. Structure-Function Relationships of the Neisserial EptA Enzyme Responsible for Phosphoethanolamine Decoration of Lipid A: Rationale for Drug Targeting. Front Microbiol 2018;9:1922. [PMID: 30186254 DOI: 10.3389/fmicb.2018.01922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
45 Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant 2020;35:298-303. [PMID: 29992261 DOI: 10.1093/ndt/gfy225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
46 Covid- O, Table SA; Drugs., Biologics Clinical Practice Guidelines Working Group*. Ivermectin treatment for Strongyloides infection in patients with COVID-19. Can Commun Dis Rep 2021;47:316-21. [PMID: 34667442 DOI: 10.14745/ccdr.v47i78a04] [Reference Citation Analysis]
47 Schaap CCM, Grotens A, de Haan AFJ, Blijlevens NMA, Langemeijer SMC. Infections during eculizumab therapy in a Dutch population of patients with paroxysmal nocturnal haemoglobinuria. Clin Microbiol Infect 2021:S1198-743X(21)00361-X. [PMID: 34197930 DOI: 10.1016/j.cmi.2021.06.030] [Reference Citation Analysis]
48 Lee JM, Lee SJ. Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report. J Korean Med Sci 2020;35:e201. [PMID: 32476306 DOI: 10.3346/jkms.2020.35.e201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
49 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
50 Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, Palomares O, Jutel M. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy 2022;77:17-38. [PMID: 34324716 DOI: 10.1111/all.15030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. Autoimmun Rev 2021;20:102800. [PMID: 33722749 DOI: 10.1016/j.autrev.2021.102800] [Reference Citation Analysis]
52 Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis. JAMA Dermatol 2021. [PMID: 34287624 DOI: 10.1001/jamadermatol.2021.2599] [Reference Citation Analysis]
53 Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, Torre A, Cossu MV, Minari C, Ballone E, Perotti A, Mileto D, Niero F, Merli S, Foschi A, Vimercati S, Rizzardini G, Sollima S, Bradanini L, Galimberti L, Colombo R, Micheli V, Negri C, Ridolfo AL, Meroni L, Galli M, Antinori S, Corbellino M. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42. [PMID: 32448770 DOI: 10.1016/j.ejim.2020.05.011] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 52.5] [Reference Citation Analysis]
54 Trujillo H, Fernández-Ruiz M, Gutiérrez E, Sevillano Á, Caravaca-Fontán F, Morales E, López-Medrano F, Aguado JM, Praga M, Andrés A. Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. Transpl Infect Dis 2021;23:e13501. [PMID: 33185971 DOI: 10.1111/tid.13501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 Baleydier F, Bernard F, Ansari M. The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers. Biomolecules 2020;10:E1112. [PMID: 32731356 DOI: 10.3390/biom10081112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Guziejko K, Czupryna P, Zielenkiewicz-Madejska EK, Moniuszko-Malinowska A. Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report. BMC Infect Dis 2022;22:182. [PMID: 35196995 DOI: 10.1186/s12879-022-07156-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mercer DK, Francis ML, Fraser-Pitt D. Antimicrobial immunotherapeutics: past, present and future. Emerg Top Life Sci 2021:ETLS20200348. [PMID: 34196722 DOI: 10.1042/ETLS20200348] [Reference Citation Analysis]
58 El Boghdadly Z, Sarwar S, Lustberg ME. Infectious Challenges with Novel Antibody–Based Therapies. Curr Infect Dis Rep 2021;23. [DOI: 10.1007/s11908-021-00753-2] [Reference Citation Analysis]
59 Raimondo A, Salzano FA, Lembo S. Disseminated mucocutaneous Candida infection during anti IL-17A therapy in a psoriatic patient. Ital J Dermatol Venerol 2021;156:400-1. [PMID: 33228332 DOI: 10.23736/S2784-8671.20.06673-0] [Reference Citation Analysis]
60 Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med 2019;40:721-39. [PMID: 31731980 DOI: 10.1016/j.ccm.2019.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
61 Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 2020;19:117-30. [DOI: 10.1080/14740338.2020.1709440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Khatri A, Malhotra P, Izard S, Kim A, Oppenheim M, Gautam-Goyal P, Chen T, Doan TL, Berlinrut I, Niknam N, Flannery S, Hirschwerk D, Epstein M, Farber B. Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies. Open Forum Infect Dis 2021;8:ofab339. [PMID: 34337096 DOI: 10.1093/ofid/ofab339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Almaimani AO. Asymptomatic Bacteriuria in Post Renal Transplant Patients: To Treat or Not? Cureus 2021;13:e15713. [PMID: 34159042 DOI: 10.7759/cureus.15713] [Reference Citation Analysis]
64 Marchesan JT. Inflammasomes as contributors to periodontal disease. J Periodontol 2020;91 Suppl 1:S6-S11. [PMID: 32533779 DOI: 10.1002/JPER.20-0157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 Pintos-Pascual I, López-Dosil M, Castillo-Núñez C, Múñez-Rubio E. Eosinophilia and abdominal pain after severe pneumonia due to COVID 19. Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30332-3. [PMID: 33279276 DOI: 10.1016/j.eimc.2020.10.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Benamu E, Hogan CA, Gomez CA. Endemic Fungi in Transplant and Immunocompromised Hosts: Epidemiology, Diagnosis, Treatment, and Prevention. Curr Treat Options Infect Dis 2020;12:30-53. [DOI: 10.1007/s40506-020-00212-x] [Reference Citation Analysis]
67 Sousa J, Taborda-Barata L, Monteiro C. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system. Expert Opin Drug Saf 2020;19:99-106. [PMID: 31661986 DOI: 10.1080/14740338.2020.1686481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 Parigi S, Licari A, Manti S, Marseglia GL, Tosca MA, Miraglia Del Giudice M, Caffarelli C, Calvani M, Martelli A, Cardinale F, Cravidi C, Duse M, Chiappini E. Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance. Acta Biomed 2020;91:e2020009. [PMID: 33004779 DOI: 10.23750/abm.v91i11-S.10311] [Reference Citation Analysis]
70 Marchesan JT, Girnary MS, Moss K, Monaghan ET, Egnatz GJ, Jiao Y, Zhang S, Beck J, Swanson KV. Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics. Periodontol 2000 2020;82:93-114. [PMID: 31850638 DOI: 10.1111/prd.12269] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
71 Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol 2022;13:869725. [DOI: 10.3389/fimmu.2022.869725] [Reference Citation Analysis]
72 Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F. Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data. Ther Clin Risk Manag 2020;16:287-97. [PMID: 32368068 DOI: 10.2147/TCRM.S228880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Mohapatra S, Ayash Kumar P, Farooq U, Jain P, khan R, Hasan N, Shamim A, Javed Ansari M, Alalaiwe AS, Aldawsari MF, Aamir Mirza M, Iqbal Z. COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues. Saudi Pharmaceutical Journal 2022. [DOI: 10.1016/j.jsps.2022.05.004] [Reference Citation Analysis]
74 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
75 Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 2019;18:415-25. [PMID: 31066297 DOI: 10.1080/14740338.2019.1612872] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
76 Meira F, Moreno-García E, Linares L, Macaya I, Tomé A, Hernández-Meneses M, Albiach L, Morata L, Letona L, Bodro M, Cózar-Llistó A, Cardozo C, Chumbita M, Pitart C, Ambrosioni J, Rico V, Agüero D, Puerta-Alcalde P, Garcia-Pouton N, Marco F, Garcia-Vidal C, Soriano A, Martínez JA. Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infect Dis Ther 2021;10:1407-18. [PMID: 34115314 DOI: 10.1007/s40121-021-00477-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Noreña I, Fernández-Ruiz M, Aguado JM. Is there a real risk of bacterial infection in patients receiving targeted and biological therapies? Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30398-0. [PMID: 33339658 DOI: 10.1016/j.eimc.2020.10.019] [Reference Citation Analysis]
78 Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, Klenerman P, Matthews PC. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. Front Med (Lausanne) 2021;8:706482. [PMID: 34490299 DOI: 10.3389/fmed.2021.706482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Abruzzese E, Luciano L, D'Agostino F, Trawinska MM, Pane F, De Fabritiis P. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection. Mediterr J Hematol Infect Dis 2020;12:e2020031. [PMID: 32395220 DOI: 10.4084/MJHID.2020.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
81 Reisinger AC, Hermann J, Vagena FR, Hackl G, Eller P. Tuberculosis sepsis after tocilizumab treatment. Clin Microbiol Infect 2020;26:1493-4. [PMID: 32512231 DOI: 10.1016/j.cmi.2020.05.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Javadzadeh S, Gkini MA, Panos GD, Adewoyin T, Bewley A. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis. Clin Exp Dermatol 2020;45:802-4. [PMID: 32212270 DOI: 10.1111/ced.14198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Leong K, Gaglani B, Khanna AK, McCurdy MT. Novel Diagnostics and Therapeutics in Sepsis. Biomedicines 2021;9:311. [PMID: 33803628 DOI: 10.3390/biomedicines9030311] [Reference Citation Analysis]
84 Diel R, Schaberg T, Nienhaus A, Otto-Knapp R, Kneitz C, Krause A, Fabri M, Mrowietz U, Bauer T, Häcker B. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie 2021;75:293-303. [PMID: 33598901 DOI: 10.1055/a-1294-1580] [Reference Citation Analysis]
85 Zabolotskikh I, Kirov M, Lebedinskii K, Protsenko D, Avdeev S, Andreenko A, Arsentyev L, Afonchikov V, Afukov I, Belkin A, Boeva E, Bulanov A, Vasiliev Y, Vlasenko A, Gorbachev V, Grigor'ev E, Grigor'ev S, Gritsan A, Eremenko A, Ershov E, Zamyatin M, Kuzovlev A, Kulikov A, Lakhin R, Leiderman I, Lenkin A, Mazurok V, Musaeva T, Nikolaenko E, Orlov Y, Petrikov S, Roitman E, Ronenson A, Smetkin A, Sokolov A, Stepanenko S, Subbotin V, Ushakova N, Khoronenko V, Tsarenko S, Shifman E, Shukevich D, Shchegolev A, Yaroshetskiy A, Yarustovsky M. Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. Annals of critical care 2020. [DOI: 10.21320/1818-474x-2020-s1-9-120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
86 Bavaro DF, Fiordelisi D, Angarano G, Monno L, Saracino A. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opin Drug Saf 2020;19:817-42. [PMID: 32394759 DOI: 10.1080/14740338.2020.1767585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
87 Oral H, Sönmezer MÇ, Yıldız AE, Hazırolan G, Metan G, İnkaya AÇ. Disseminated Brucella melitensis infection following canakinumab treatment. Travel Med Infect Dis 2021;45:102227. [PMID: 34856407 DOI: 10.1016/j.tmaid.2021.102227] [Reference Citation Analysis]
88 Ritvo PG, Klatzmann D. Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells. Front Immunol 2019;10:250. [PMID: 30873158 DOI: 10.3389/fimmu.2019.00250] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
89 Langereis JD, van den Broek B, Franssen S, Joosten I, Blijlevens NMA, de Jonge MI, Langemeijer S. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Adv 2020;4:3615-20. [PMID: 32766853 DOI: 10.1182/bloodadvances.2020002497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
90 Braun J, Kiltz U, Müller-Ladner U. [Is complete immunity against measles a realistic target for patients with rheumatic diseases and how can it possibly be achieved?]. Z Rheumatol 2020;79:922-8. [PMID: 32945951 DOI: 10.1007/s00393-020-00877-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Philippot Q, Casanova JL, Puel A. Candidiasis in patients with APS-1: low IL-17, high IFN-γ, or both? Curr Opin Immunol 2021;72:318-23. [PMID: 34455138 DOI: 10.1016/j.coi.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Venkatesan A. Immune-mediated encephalitis for the infectious disease specialist. Curr Opin Infect Dis 2019;32:251-8. [PMID: 31021956 DOI: 10.1097/QCO.0000000000000546] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Riestra S, Taxonera C, Zabana Y, Carpio D, Beltrán B, Mañosa M, Gutiérrez A, Barreiro-de Acosta M. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. Gastroenterol Hepatol 2021;44:51-66. [PMID: 32828562 DOI: 10.1016/j.gastrohep.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Ostrov BE, Amsterdam D. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases. Immunol Invest 2021;50:833-56. [PMID: 33941025 DOI: 10.1080/08820139.2021.1900863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]